BioNTech SE (BNTX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

BioNTech SE (BNTX) is down 6.4% since the beginning of the year. At $89 per share, BNTX is trading 28.1% below its 52-week high of $124. Investors who bought $1,000 worth of BNTX shares 5 years ago would now be looking at an investment worth $423.

BioNTech SE (BNTX) has returned -6.37% so far this year and -21.18% over the past 12 months.

Based on dividend-adjusted daily data since Oct 10, 2019, BNTX's average daily return is +0.22%, while the average monthly return is +4.16%. At this rate, an investment would double in approximately 1.4 years.

Historically, 53% of months were positive and 47% were negative. The best month was Apr 2021 with a return of +72.4%, while the worst month was Dec 2020 at -34.4%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 6 months.

On a daily basis, BNTX closed higher 49% of trading days. The best single day was Mar 17, 2020 with a return of +66.5%, while the worst single day was Mar 19, 2020 at -35.5%.

BioNTech SE has an annualized alpha of 52.07%, beta of 0.86, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since October 11, 2019.

• This stock captured 128.29% of S&P 500 Index gains but only 66.86% of its losses - a favorable profile for investors.
• R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

BNTX ranks 15 for risk / return — in the bottom 15% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for BioNTech SE (BNTX) and compare them to S&P 500 Index.

BioNTech SE provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.

The table displays the monthly dividend distributions for BioNTech SE. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the BioNTech SE. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the BioNTech SE was 82.08%, occurring on Aug 5, 2024. The portfolio has not yet recovered.

The current BioNTech SE drawdown is 79.61%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of BioNTech SE over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how BioNTech SE is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.